Abstract: A method and/or system for making determinations regarding samples from biologic sources. A computer implemented method and/or system can be used to automate parts of the analysis.

Abstract: A method of obtaining a corrected image of a microarray includes acquiring an image of a microarray including a target spot, and processing the image to correct for background noise and chip misalignment. The method also includes analyzing the image to identify a target patch, edit debris, and correct for ratio bias; and detecting single copy number variation in the target spot using an objective statistical analysis that includes a t-value statistical analysis. The method provides statistically robust computational processes for accurately detecting genomic variation at the single copy level.

Abstract: A method and/or system for making determinations regarding samples from biologic sources. A computer implemented method and/or system can be used to automate parts of the analysis.

Abstract: A method and/or system for making determinations regarding samples from biologic sources. A computer implemented method and/or system can be used to automate parts of the analysis.

Abstract: A method and/or system for making determinations regarding samples from biologic sources. A computer implemented method and/or system can be used to automate parts of the analysis.

Abstract: A method of obtaining a corrected image of a microarray includes acquiring an image of a microarray including a target spot, and processing the image to correct for background noise and chip misalignment. The method also includes analyzing the image to identify a target patch, edit debris, and correct for ratio bias; and detecting single copy number variation in the target spot using an objective statistical analysis that includes a t-value statistical analysis. The method provides statistically robust computational processes for accurately detecting genomic variation at the single copy level.

Abstract: A method for treating an organ donor prior to harvesting organ to reduce graft rejection in a recipient. An amount effective to reduce graft rejection of at least one compound selected from the group consisting of compounds having formulas I, II, III, IV, V, VI, and VII is administered to the organ donor: wherein Y is X is F or Cl; and the remaining groups are as defined in the specification.

Abstract: A method for treating an organ donor prior to harvesting organ to reduce graft rejection in a recipient.

Abstract: Preliminary clinical studies in humans have now been done which show both the efficacy of 10-propargyl-10dAM and a preferred dosage schedule for such treatments. In addition, it has now been determined that combinations of 10-propargyl-10-deazaaminopterin (preferably highly purified forms, substantially free of 10-deazaaminopterin) with taxols exhibit synergistic effectiveness in the treatment of tumors. 10-propargyl-10-deazaaminopterin and a taxol in therapeutically effective amounts can be administered concurrently, one right after the other, or with a period of time in between.

Abstract: Highly purified 10-propargyl-10-deazaaminopterin (10-propargyl-10dAM) compositions tested in xenograft models for their efficacy against human tumors are shown to be far superior to methotrexate ("MTX") and are even superior to the newer clinical candidate edatrexate ("EDX"). Moreover, 10-propragyl-10dAM showed a surprising ability to cure tumors such that there was no evidence of tumor growth several weeks after the cessation of therapy. Thus, highly purified compositions containing 10-propargyl-10dAM can be used to treat human tumors, particularly human mammary tumors and human lung cancer.

Abstract: Antiinflammatory and antineoplastic 5-deazaaminopterins and 5,10-dideazaaminopterins and their 5 and 10 alkyl analogs. A method for the treatment and prevention of inflammatory disease, such as rheumatoid arthritis, and for suppression and prevention of neoplastic growth in tumors and in blood forming tissues. A process for preparation of 10-deazaaminopterins.

Abstract: A process is provided for the preparation of 10-deazaaminopterins and 5,10- and 8,10-dideazaaminopterins starting from the corresponding homoterephthalic acid diester coupling the corresponding dicarboxylic acid diester having the formula: ##STR1## with the corresponding diaminopterin 6-methylene halide having the formula: ##STR2## thereby forming a pteroic acid diester having the formula: ##STR3## hydrolysing the two ester groups to form the corresponding carboxylic acid groups, and then monodecarboxylating the diacid, thereby removing the carboxylic acid group attached to the carbon alpha to the A group and forming a pteroic acid.

Abstract: There is disclosed certain heteroaroyl 10-deazaaminopterin and 5, 10 and 8, 10 di deazaminopterin compounds and their use for treatment of rheumatoid arthritis and related diseases and preparative process.Also disclosed are 10 alkenyl-(and alkynyl) 10-deazaminopterins also disclosed for treatment of rheumatoid arthritis and for leukemia and ascites tumors and preparative process.

Abstract: A method of decreasing the toxicity of chemical therapeutic agents administered in cancer chemotherapy including adminstration to a patient undergoing chemotherapy. This reduction in toxicity can be accomplished by administering an effective amount of S-3-(3-methylaminopropylamino)propyl dihydrogen phosphorothioate. Methods of inducing mucolytic activity and reducing toxicity of acetominophen overdose are also discussed. Such activities are induced through the administration of S-3-(3-methylaminopropylamino)propyl dihydrogen phosphorothioate.

Abstract: 5,10-Dialkyl substituted 5,10-dideazaaminopterins and a cyclized derivative thereof are disclosed as potent antineoplastic agents. Also disclosed is an improved process for the preparation of 10-ethyl-10-deazaaminopterin using the intermediate methyl 4-[[2-(2,4-diamino-6-pteridinyl)-1-ethyl]ethenyl]benzoate.

Abstract: It is disclosed that 5-methyl-5-deazamethotrexate and 5-methyl-5-deaza-10-ethylaminopterin are more than 10 times as potent as 5-deazamethotrexate in the L1210 cell growth inhibition test.

Abstract: A system for supplying hot water into a dwelling or the like. The system includes a continuous circulating hydraulic loop for distribution to fixtures and heat exchange units. A storage circuit is employed to add heated water as needed to the loop. A water heating circuit supplies solar energy to the storage system for eventual use in the continuous loop. The storage circuit and the water heating circuit are controlled to provide water on an optimum efficiency basis. Feed water is also supplied to the system through the solar panels of the water heating system.

Abstract: A solar energy system employing solar panels used to heat water. The system includes a boiler with the vent for the boiler being located beneath the solar panels to distribute exhaust heat thereto. A structure is defined to allow venting of the enclosed area behind the panels. The panels are constructed with multiple sheets of plastic as glazing which are retained by means of interlocking elements and adhesive.

Abstract: A system for space heating for a building employing structural elements of the building as heating conduits. Girder pairs are employed as manifold conduits and joist pairs are employed as distribution conduits for the present system. The crawl space of the building is used for the return air and becomes a plenum therefor.